Line One Nutrition, Inc. – Trademark Portfolio
Entity Type: 03
Line One Nutrition, Inc. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 11 trademarks are registered. Notable registered marks include LEAN PILLS, MASS PILLS, PUMP POWDER, RESET PILLS, and MUSCLE PILLS. The owner is based in Austin, TX.
7801 Shoal Creek Blvd., Unit #155
Austin, TX 78757
Showing of trademarks Trademarks
Trademark Classifications
Line One Nutrition, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Line One Nutrition, Inc. have?
Line One Nutrition, Inc. has 12 U.S. trademarks filed with the USPTO. Of these, 11 registered, 1 cancelled.
What trademark classes does Line One Nutrition, Inc. file in?
Line One Nutrition, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 25 (Clothing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Line One Nutrition, Inc.'s most well-known trademarks?
Line One Nutrition, Inc.'s registered trademark portfolio includes well-known marks such as LEAN PILLS, MASS PILLS, PUMP POWDER, RESET PILLS, and MUSCLE PILLS. These are among 11 currently registered trademarks in the portfolio.
What is Line One Nutrition, Inc.'s trademark registration success rate?
Line One Nutrition, Inc. has a 92% trademark registration rate, with 11 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.